APLN and cancer: To further test whether Apelin cooperates with VEGFR signaling and whether the combinational blockage of both could be exploited in anti‐cancer treatment, we treated shRenilla and shApln E0771 cell‐bearing C57BL/6J mice with a specific anti‐VEGFR2 antibody (DC101 clone) and obtained similar results as with sunitinib and axitinib treatments (Fig EV4C).